Arantxa González

Sep 29, 2024 | laverdad.es | Arantxa González

ARANTXA GONZÁLEZLunes, 30 de septiembre 2024, 00:42Necesitas ser suscriptor para acceder a esta funcionalidad. Aunque algunas ya lo hacen, me gustaría pedir a las cadenas de televisión que impartieran cursos del lenguaje de signos a algunos de sus presentadores. Lo mismo que son capaces de traducir a otros idiomas extranjeros, muchos agradeceríamos que aprendieran ese lenguaje de signos en ... Este contenido es exclusivo para suscriptores

Sep 5, 2024 | nature.com | Fang-Fei Wei |Pierpaolo Pellicori |Joao Ferreira |Arantxa González |De-Wei An |Chen Liu | +10 more

AbstractNone of the spironolactone trials in heart failure (HF) assessed the blood pressure (BP) responses to exercise, while conflicting results were reported for exercise capacity. In the HOMAGE trial, 527 patients at increased HF risk were randomized to usual treatment with or without spironolactone (25–50 mg/day). The current substudy included 113 controls and 114 patients assigned spironolactone, who all completed the incremental shuttle walk test at baseline and months 1 and 9.

Jul 9, 2024 | onlinelibrary.wiley.com | Arantxa González |John Cleland

Aims Fibrosis is a common feature of many chronic diseases, including heart failure, which can have deleterious effects on cardiac structure and function that are associated with adverse outcomes. By-products of collagen synthesis and degradation, such as carboxy- and amino-terminal pro- or telo-peptides of collagen type I and III (PICP, PINP, PIIINP, and CITP) have been extensively investigated as markers of fibrosis.